MAIA Biotechnology (MAIA) Free Cash Flow (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Free Cash Flow for 6 consecutive years, with -$5.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 26.39% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$20.0 million (down 22.27% YoY), while the FY2025 annual figure was -$18.8 million, down 20.0% from the prior year.
• Free Cash Flow improved to -$5.3 million in Q1 2026 per MAIA's latest filing, from -$7.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$2.0 million in Q2 2022 and bottomed at -$7.0 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$3.8 million across 5 years, with a median of -$3.6 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 229.38% — and 2023, when it climbed 26.9%.
• MAIA Biotechnology's Free Cash Flow stood at -$2.9 million in 2022, then sank by 35.35% to -$4.0 million in 2023, then gained by 2.11% to -$3.9 million in 2024, then plunged by 79.64% to -$7.0 million in 2025, then grew by 24.35% to -$5.3 million in 2026.
• Business Quant data shows MAIA's Free Cash Flow at -$5.3 million in Q1 2026, -$7.0 million in Q4 2025, and -$3.5 million in Q3 2025.